Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate ...

MONTREAL—Denosumab significantly prolongs bone metastasis-free survival (BMFS) and delays time to bone metastasis in men with castration-resistant prostate cancer (CRPC), according to data presented ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

Triple negative breast cancer (TNBC) is usually detected at later stages. Unfortunately, by this time the cancer has moved or metastasized to other tissues throughout the body. One of the most common ...

"Researchers should start recognizing patients with de novo metastasis as a distinct population from patients with distant recurrence and investigate their intrinsic differences." — Chloe C. Su, BS, ...

Source: Getty Images Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD. Radium-223 provided ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its ...